BR112014001530A2 - formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzeno sulfonamida - Google Patents

formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzeno sulfonamida

Info

Publication number
BR112014001530A2
BR112014001530A2 BR112014001530A BR112014001530A BR112014001530A2 BR 112014001530 A2 BR112014001530 A2 BR 112014001530A2 BR 112014001530 A BR112014001530 A BR 112014001530A BR 112014001530 A BR112014001530 A BR 112014001530A BR 112014001530 A2 BR112014001530 A2 BR 112014001530A2
Authority
BR
Brazil
Prior art keywords
carbonyl
chloro
tert
phenyl
butyl
Prior art date
Application number
BR112014001530A
Other languages
English (en)
Other versions
BR112014001530B1 (pt
Inventor
Ho Bert
H Igo David
Shah Deven
Bis Joanna
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BR112014001530A2 publication Critical patent/BR112014001530A2/pt
Publication of BR112014001530B1 publication Critical patent/BR112014001530B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

resumo patente de invenção: "formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzeno sulfonamida". a presente invenção refere-se a novas formas triidratadas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil] benzenossulfonamida. uma modalidade da presente invenção está direcionada a uma forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-25 fenil]-benzenossulfonamida (daqui em diante "composto a - forma triidrata cristalina i"), em que a forma cristalina é caracterizada por meio de um padrão de difração de pó de raios x compreendendo os ângulos de difração (º2?), quando medidos empregando a radiação por cu ka, de cerca de 4,5, 9,0, 13,6, 13,9, 15,8, 17,8, 18,2, 18,5, 19,1, 19,9, 20a, 21,2, 22,1, 22,7, 24,3, 25,0, 25,6, 26,2, 26,8, 27,3, 27,6, 28,0, 28,8, e 30,8.
BR112014001530-9A 2011-07-22 2012-07-20 Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma BR112014001530B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510555P 2011-07-22 2011-07-22
US61/510,555 2011-07-22
PCT/US2012/047512 WO2013016155A1 (en) 2011-07-22 2012-07-20 Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

Publications (2)

Publication Number Publication Date
BR112014001530A2 true BR112014001530A2 (pt) 2017-02-14
BR112014001530B1 BR112014001530B1 (pt) 2022-05-31

Family

ID=47601458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001530-9A BR112014001530B1 (pt) 2011-07-22 2012-07-20 Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma

Country Status (12)

Country Link
US (2) US9139526B2 (pt)
EP (1) EP2739283A4 (pt)
JP (1) JP6122002B2 (pt)
CN (1) CN103841971B (pt)
AU (1) AU2012287233B2 (pt)
BR (1) BR112014001530B1 (pt)
CA (1) CA2842894A1 (pt)
IL (2) IL230598A0 (pt)
MX (1) MX2014000659A (pt)
RU (1) RU2607514C2 (pt)
WO (1) WO2013016155A1 (pt)
ZA (1) ZA201400843B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2748146T3 (en) * 2011-07-22 2017-05-22 Chemocentryx Inc CRYSTALLINE FORM OF THE SODIUM SALT OF 4-TERT-BUTYL-N- [4-CHLOR-2- (1-OXY-PYRIDINE-4-CARBONYL) -PHENYL] -BENZEN SULPHONAMIDE
BR112014001505A2 (pt) * 2011-07-22 2017-02-14 Chemocentryx Inc formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2- (1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida
MX2014000659A (es) * 2011-07-22 2014-07-09 Chemocentrix Inc Formas polimorficas de la sal de sodio de 4-ter-butil-[4-cloro-2-( 1-oxi-piridina-4-carbonil)-fenil]-bencensulfonamida.
EP3141235A1 (en) * 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
CA3224013A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399903A1 (en) * 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
ES2369720T5 (es) 2002-11-18 2014-11-06 Chemocentryx, Inc. Arilsulfonamidas
JP2007527918A (ja) 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
WO2005113513A2 (en) 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
PL2046762T3 (pl) * 2006-07-14 2011-07-29 Chemocentryx Inc Triazolilofenylobenzenosulfonamidy
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
DK2748146T3 (en) * 2011-07-22 2017-05-22 Chemocentryx Inc CRYSTALLINE FORM OF THE SODIUM SALT OF 4-TERT-BUTYL-N- [4-CHLOR-2- (1-OXY-PYRIDINE-4-CARBONYL) -PHENYL] -BENZEN SULPHONAMIDE
BR112014001505A2 (pt) * 2011-07-22 2017-02-14 Chemocentryx Inc formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2- (1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida
MX2014000659A (es) * 2011-07-22 2014-07-09 Chemocentrix Inc Formas polimorficas de la sal de sodio de 4-ter-butil-[4-cloro-2-( 1-oxi-piridina-4-carbonil)-fenil]-bencensulfonamida.

Also Published As

Publication number Publication date
JP6122002B2 (ja) 2017-04-26
US20160039762A1 (en) 2016-02-11
US9464054B2 (en) 2016-10-11
RU2607514C2 (ru) 2017-01-10
IL285666A (en) 2021-09-30
US20140155438A1 (en) 2014-06-05
WO2013016155A1 (en) 2013-01-31
CA2842894A1 (en) 2013-01-31
EP2739283A1 (en) 2014-06-11
IL230598A0 (en) 2014-03-31
AU2012287233A1 (en) 2014-02-13
CN103841971B (zh) 2016-09-14
US9139526B2 (en) 2015-09-22
EP2739283A4 (en) 2015-03-11
CN103841971A (zh) 2014-06-04
MX2014000659A (es) 2014-07-09
AU2012287233B2 (en) 2017-07-20
RU2014104991A (ru) 2015-08-27
ZA201400843B (en) 2015-10-28
JP2014521645A (ja) 2014-08-28
BR112014001530B1 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
BR112014001530A2 (pt) formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzeno sulfonamida
BR112014001505A2 (pt) formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2- (1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida
FI3351539T3 (fi) Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä
PH12016500169A1 (en) Polymorph of syk inhibitors
RU2015112098A (ru) Кристаллы производных диспиропирролидина
BR112014030365A2 (pt) síntese de composto antiviral
BR112015027079A8 (pt) composição aquosa, métodos para a obtenção de um benefício antiperspirante, método para a fabricação de uma composição antiperspirante aquosa, sal antiperspirante e uso de uma composição antiperspirante
IL230468B (en) Crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
AR077208A1 (es) Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
BR112015027333A2 (pt) composição aquosa, método para a obtenção de um benefício antitranspirante, método para a fabricação de uma composição antitranspirante aquosa e utilização de uma composição
BR112013003087A2 (pt) forma cristalina de composto de pirimidio[6,1-a]-isoquinolin-4-ona
BR112016007460A2 (pt) processo para a preparação de xanthohumol
BR112015013995A2 (pt) emulsão estabilizada por partículas sólidas, processo para a preparação de uma emulsão estabilizada por partículas sólidas, e, uso de emulsão estabilizada por partículas sólidas
HRP20220031T1 (hr) Kristalni trihidratni oblik (3s,3s') 4,4'-disulfanedilbis (3-aminobutan 1-sulfonske kiseline)
CO6700139A1 (es) Forma cristalina delta de la sal de arginina de perdinoprilo, su procedimiento de preparación y las composiciones famacéuticas que la contienen
SA114350792B1 (ar) شكل متبلر جديد من ملح الـبيميرولاست
BR112014019664A8 (pt) Método para a manufatura de uma solução aquosa de um sal metálico alcalino de carboximetil frutano
BR112014030034A2 (pt) método para a estabilização de gesso beta semi-hidratado
BR112017004166A2 (pt) sal de derivado de cefalosporina, forma sólida cristalina do mesmo e método para produzir o mesmo
CA2901220C (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
PH12017500764A1 (en) Agrochemical formulation
CZ2017762A3 (cs) Soli a krystalické formy venetoclaxu
EP3511317A4 (en) NEW CRYSTALLINE SODIUM SALT FORM OF SACUBITRIL
EA201690622A1 (ru) Соль дигидрофосфат тенофовира дизопроксила

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2012, OBSERVADAS AS CONDICOES LEGAIS